Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
21 August 2020
Costs of deception – Big fine from Australian watchdog shows need for credible privacy statements
21 Juli 2020
Can predictive analytics prevent employee misconduct?
21 Juli 2020
Digital forensics in investigations and the growing data burden
21 Juli 2020
Big data and Modern Slavery – Progress not panacea
21 Juli 2020
Using big data to fight financial crime
21 Juli 2020
Regulators lead businesses in monitoring of misconduct
15 Juli 2020
Where is the balance now? Preliminary injunctions in pharmaceutical patent proceedings in 2020 and beyond
25 Juni 2020
CJEU rules that providing free samples of non-prescription drugs to pharmacists is permitted
18 Juni 2020
Future Cities Series: How planning and zoning rules can drive post-Covid development
9 Juni 2020
Governance: Corporate Insolvency and Governance Bill: impact on supply chains and their customers (UK)
26 Mai 2020
Manufacturing medicines in Australia: examining the need for increased domestic capability
12 Mai 2020
Patent and Pharma Update, May 2020
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane